Enliven Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
ELVN$51.55+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $100,141 | $75,536 |
| Marketable securities | 153,007 | — |
| Restricted cash | 54 | — |
| Prepaid expenses and other current assets | 2,949 | 2,217 |
| Contingent value right asset | 10,000 | — |
| Total current assets | 266,151 | 77,753 |
| Property and equipment, net | 742 | 890 |
| Operating lease right-of-use assets | 320 | 626 |
| Deferred offering costs | 563 | 3,975 |
| Restricted cash | — | 54 |
| Other long-term assets | 4,091 | — |
| Total assets | $271,867 | $83,298 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $532 | $3,438 |
| Accrued expenses and other current liabilities | 15,362 | 6,277 |
| Contingent value right liability | 10,000 | — |
| Total current liabilities | 25,894 | 9,715 |
| Long-term liabilities | 67 | 659 |
| Total liabilities | 25,961 | 10,374 |
| Commitments and contingencies (Note 9): | ||
| Convertible preferred stock, par value $0.0001; authorized shares - none and 61,730,064 at December 31, 2023 and 2022, respectively; issued and outstanding shares - none and 61,730,064 at December 31, 2023 and 2022, respectively; liquidation preference - $0 and $140,520 at December 31, 2023 and 2022, respectively | — | 149,749 |
| Stockholders' equity (deficit): | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000 and none at December 31, 2023 and 2022, respectively; issued and outstanding shares - none | — | — |
| Common stock, par value $0.001 and $0.0001 at December 31, 2023 and 2022, respectively; authorized shares - 100,000,000 and 26,264,364 at December 31, 2023 and 2022, respectively; issued and outstanding shares - 41,292,027 and 3,570,019 at December 31, 2023 and 2022, respectively | 41 | 1 |
| Additional paid-in capital | 400,172 | 6,038 |
| Accumulated other comprehensive income | 141 | — |
| Accumulated deficit | (154,448) | (82,864) |
| Total stockholders’ equity (deficit) | 245,906 | (76,825) |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $271,867 | $83,298 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.